What Naturecell does

NatureCell Co., Ltd. is a South Korea-based regenerative medicine company founded in 2001 that develops adult stem cell technologies, principally mesenchymal stem cells derived from amniotic membrane and adipose tissue, manufactured in GMP-certified facilities. Its product portfolio spans clinical-stage therapeutics (JointStem, the world's first stem cell treatment for knee osteoarthritis, and Vascostem CLI, an investigational therapy for Critical Limb Ischemia that received FDA IND approval in January 2025), consumer-facing services (amniotic stem cell banking for newborns), premium skincare under the Dr. Jucre sub-brand (MSC Ample, Gold Care Set, stem cell shampoo built on a proprietary culture medium containing 565 protein growth factors), and HACCP-certified vegan wellness beverages produced via Biostar's patented technology.

The company monetizes through a mix of consumer subscriptions (stem cell banking), e-commerce unit sales (Dr. Jucre via Naver Smart Store, vegan beverages via retail), and future per-treatment pricing for FDA-approved therapies, with Vascostem CLI targeted at greater than $50,000 per dose in the U.S. market upon a projected 2029 launch. Go-to-market is hybrid: enterprise field sales and FDA regulatory engagement for the therapeutic pipeline through wholly-owned subsidiary Nature Cell America Inc., and direct-to-consumer online consultation and e-commerce for banking and consumer products. The company is pursuing an aggressive U.S. expansion anchored by a 100,000-square-foot Biostar Stem Cell Campus in Baltimore, Maryland (developed in two phases through 2031, projecting 500 jobs and one million doses of annual capacity), and is supported by a Scientific Advisory Agreement with 2019 Nobel Laureate Professor Gregg L. Semenza of Johns Hopkins University. The company is led by Chairman Jeong-Chan Ra and operates an exclusive commercialization partnership with Biostar Research Institute for its core stem cell technologies.

Name

Naturecell

Legal name

NatureCell Co., Ltd.

Website

https://naturecell.co.kr

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Stem cell therapy
• Regenerative medicine
• Stem cell banking
• Biotech cosmetics
• Health beverages

Headquarters

HQ city

Yongdungpo

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Stem Cell Therapies (FDA-Approved Pipeline): High-value stem cell therapy treatments commercialized upon regulatory approval. The company targets a U.S. market launch in 2029 with anticipated treatment pricing exceeding $50,000 per dose for Vascostem CLI. Revenue is generated through one-time treatment procedures following FDA approval.
2. Amniotic Stem Cell Banking: Consumer subscription-style service for storing a newborn's amniotic stem cells at birth. Families pay for collection, processing, and long-term storage in GMP-certified ultra-low temperature facilities. Cells have potential future use for the child and family members.
3. Stem Cell Culture Medium Cosmetics (Dr. Jucre): Premium skincare product line (Dr. Jucre brand) powered by proprietary stem cell culture medium technology. Products include MSC Ample, stem cell shampoo, and Gold Care Set. Sold via Naver Smart Store e-commerce platform.
4. Vegan Health Beverages: Vegan wellness beverages using Biostar's patented technology and NatureCell's specialized know-how. Produced in HACCP-certified facilities. Positioned as a premium bio-vegan health beverage.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

NatureCell is a regenerative medicine company that develops and commercializes adult mesenchymal stem cell-based products and services. Its offerings include investigational stem cell therapies (JointStem for knee osteoarthritis and Vascostem CLI for Critical Limb Ischemia), amniotic stem cell banking for newborns, the Dr. Jucre premium skincare line powered by stem cell culture medium, and vegan health beverages. Manufacturing is conducted in GMP-certified facilities, with a 100,000-square-foot Biostar Stem Cell Campus under development in Baltimore, Maryland.

Product overview

NatureCell is a South Korea-based regenerative medicine company founded in 2001, operating world-class GMP-certified facilities. The company offers a portfolio of stem cell-based products and services including: (1) Investigational therapies - JointStem (world's first stem cell treatment for knee osteoarthritis) and Vascostem CLI (for Critical Limb Ischemia) in clinical development; (2) Consumer products - Dr. Jucre skincare line (MSC Ample, Stem Cell Shampoo, Gold Care Set) leveraging stem cell culture medium technology; (3) Vegan Health Beverage - bio-vegan wellness drink; (4) Amniotic Stem Cell Storage - banking service for newborn amniotic stem cells. The company also operates a 100,000 sq ft manufacturing hub in Baltimore, Maryland (1401 Severn St) planned through 2031.

Differentiator

Problem solved

Functional benefit

Brands

• Dr. Jucre: Premium skincare brand using stem cell culture medium technology derived from human fat tissue for advanced reverse-aging care for skin and hair.
• Vegan Health Beverage

Products and services

• JointStem The world's first stem cell treatment for knee osteoarthritis, developed through exclusive partnership with Biostar Research Institute. Uses adipose-derived mesenchymal stem cells for regenerative treatment of degenerative arthritis.
• Vascostem CLI Investigational therapy for Critical Limb Ischemia (CLI) using stem cell technology. Developed with Scientific Advisory Agreement from 2019 Nobel Laureate Prof. Gregg L. Semenza for clinical development and FDA approval strategy. Targeted treatment price exceeds $50,000 per dose upon U.S. market launch in 2029.
• Amniotic Stem Cell Storage Banking service for amniotic stem cells collected from the amniotic membrane at birth. Stem cells are stored at biological age 0 with highest vitality and longest telomeres, providing potential for future regenerative medicine treatments for the child and family members. Customers enroll via online consultation booking on the NatureCell website.
• Dr. Jucre (Stem Cell Culture Medium Cosmetics) Premium skincare line powered by proprietary stem cell culture medium technology derived from human fat tissue. Built on 3R Science philosophy (Reverse-aging, Regeneration, Rejuvenation) with 565 types of protein growth factors. Product range includes MSC Ample (100% stem cell culture medium), NatureCell Stem Cell Shampoo, and 24K Gold-infused Gold Care Set. Sold through Naver Smart Store in South Korea.
• Vegan Health Beverage Vegan wellness beverage integrating NatureCell's specialized know-how with Biostar's patented technology. Made with 100% vegan ingredients, free from dairy, eggs, and animal-derived ingredients, produced in a HACCP-certified facility with advanced production standards.

Quantifiable outcome

• World's first stem cell treatment for knee osteoarthritis (JointStem) — commercially developed
• +5 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

• Professor Gregg L. Semenza (Johns Hopkins University)flagshipStrategic or Co-development Partner · 13 February 2026NatureCell America Inc. entered a Scientific Advisory Agreement with 2019 Nobel Laureate Professor Gregg L. Semenza of Johns Hopkins University to advise on clinical development and FDA approval strategy for Vascostem CLI, an investigational therapy for Critical Limb Ischemia. Semenza provides guidance on optimizing HIF signaling pathways linked to cell therapy and navigating U.S. FDA regulatory processes including IND filing and RMAT designation.
• Biostar Research InstituteflagshipStrategic or Co-development PartnerExclusive partnership for the commercialization of core technologies with Biostar Research Institute, including proprietary stem cell culture technology for human application of mesenchymal stem cells, the world's largest adipose-derived stem cell storage bank operations, and Biostar's patented technology for vegan beverages.
• Samsung BiologicscoreStrategic or Co-development PartnerSamsung Biologics is listed as a Korean company that has invested in Maryland's life sciences sector alongside NatureCell. Both companies are supported by the Maryland-Korea Trade Desk established to facilitate bilateral partnerships between Korean companies and Maryland's life sciences ecosystem.
• Impulse BiomedminorOthersSouth Africa's Impulse Biomed joined Maryland's medtech sector at The LaunchPort in Baltimore alongside NatureCell's presence. Mentioned as a co-investment win at the SelectUSA Investment Summit.
• Maryland-Korea Trade DeskcoreGTM or Marketing PartnerA bilateral trade desk established to support Korean companies including Samsung Biologics and NatureCell that have invested in Maryland's life sciences sector. Facilitated by Maryland officials as part of the state's economic development strategy to attract and retain Korean FDI in the biotech sector.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Cytori Therapeutics (now PLUS Therapeutics spin-off Era): Historical developer of adipose-derived regenerative cell therapies (Celution system) targeting CLI and scleroderma. Closest analog on the adipose-derived MSC sourcing approach used in NatureCell's JointStem and Vascostem CLI platform.
• Holostem Terapie Avanzate: European (Italy-based) cell therapy developer focused on autologous epithelial stem cell treatments. Comparable boutique cell therapy structure with focused GMP manufacturing for advanced therapy medicinal products (ATMPs).

Regional players

• Pharmicell (formerly Korea Stem Cell): Korean stem cell therapy company with overlapping MSC-based regenerative medicine pipeline (e.g., Cartistem for cartilage, Cellgram for AMI). Most relevant Korean peer sharing the home regulatory and clinical environment.

Others

• Samsung Biologics: Korean life sciences CDMO and biotech investor also active in Maryland's life sciences sector alongside NatureCell. Comparable Korean life sciences peer establishing U.S. footprint and an ecosystem partner enabling potential CDMO relationships.

Direct peers

• Athersys: U.S. company developing MultiStem, an allogeneic adult stem cell therapy for ischemic stroke, ARDS, and trauma. Comparable adult-derived MSC product platform targeting ischemic and inflammatory indications including CLI-adjacent conditions.
• Mesoblast: Australia-listed mesenchymal stem cell therapy company developing remestemcel-L for inflammatory and cardiovascular indications. Closest direct competitor to NatureCell's MSC platform with multiple late-stage trials in CLI-adjacent and inflammatory indications.
• BrainStorm Cell Therapeutics: U.S./Israeli developer of NurOwn, an autologous MSC-based cell therapy for neurodegenerative and inflammatory diseases. Same MSC manufacturing backbone and regulatory pathway targeting NDA/BLA-level approvals.
• Capricor Therapeutics: Biopharma developing cell therapy (CAP-1002, allogeneic cardiosphere-derived cells) for Duchenne muscular dystrophy and cardiac indications. Compares on cell therapy modality, GMP manufacturing needs, and clinical/regulatory execution model.
• Pluristem Therapeutics: Israeli cell therapy company using placenta-derived mesenchymal-like cells (PLX) for peripheral artery disease/CLI and musculoskeletal indications. Comparable placenta/MSC-based pipeline aimed at the same vascular and orthopedic indications as NatureCell.

Broad incumbents

• Vericel: U.S. commercial-stage cell therapy company (MACI for cartilage repair, Epicel for burns). Mature, established peer demonstrating scalable commercial cell therapy execution and orthopedic commercialization, the model NatureCell aims to replicate in the U.S.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Naturecell